UF Explores Ozempic-Style Implant for Treating Feline Obesity

Pilot study tests long-acting GLP-1 weight loss therapy in cats

Feb. 23, 2026 at 10:49pm

Got story updates? Submit your updates here. ›

Researchers at the University of Florida College of Veterinary Medicine are conducting a pilot study to test whether a GLP-1-based weight loss therapy, similar to medications used in human obesity treatment, could help address the growing problem of feline obesity. The study is evaluating a long-acting implant called MEOW-1 that slowly releases the medication over several months.

Why it matters

Feline obesity is a major health issue, with nearly 60% of cats in the U.S. classified as overweight or obese. This can lead to serious conditions like diabetes, orthopedic problems, and cancer. GLP-1 therapies may be particularly relevant for cats, as most feline diabetes is Type 2, making cats more responsive to insulin-regulating and appetite-suppressing treatments.

The details

The MEOW-1 implant is slightly larger than a microchip and is administered subcutaneously. In the placebo-controlled study, two-thirds of the 50 enrolled cats receive the drug, while one-third serve as controls. Researchers monitor the cats' weight, appetite, and metabolic markers over 3-6 months. The long-acting design aims to address challenges owners face with administering medications or managing feeding protocols.

  • The study began in December 2025.
  • Researchers expect to publish full results by summer 2026.
  • If successful, the product could reach the veterinary market by 2028.

The players

Chen Gilor

A veterinary researcher at the University of Florida College of Veterinary Medicine who is leading the MEOW-1 pilot study.

Kaela Navarro

A veterinarian practicing in Gainesville, Florida, who has expressed concerns about the potential for appetite suppression with the MEOW-1 implant.

Kimberly Hall de Vries

A veterinarian in Florida who emphasized that obesity increases risks for serious health issues in cats, including diabetes, orthopedic disease, and cancer.

Got photos? Submit your photos here. ›

What they’re saying

“One of the goals is not just treating obesity, but preventing diabetes before it develops.”

— Chen Gilor, Veterinary Researcher

“Cat owners may be reluctant to use medications that significantly reduce appetite, since cats are prone to hepatic lipidosis if they stop eating.”

— Kaela Navarro, Veterinarian

“Ideal feline body condition should resemble an hourglass shape when viewed from above, with a visible waistline behind the ribs.”

— Kimberly Hall de Vries, Veterinarian

What’s next

Researchers plan to pursue U.S. Food and Drug Administration approval for the MEOW-1 implant within the next 18 to 24 months.

The takeaway

This study reflects a broader shift toward using human pharmaceutical discoveries to improve animal health outcomes. If successful, GLP-1-based veterinary therapies could provide new tools for managing obesity-related disease and improving quality of life for millions of companion cats worldwide.